Biotech's High-Stakes Bet: Opus & EyePoint

Biotech stocks Opus Genetics and EyePoint Pharmaceuticals are making waves, each valued at $1.4 billion, as they develop treatments for serious retinal conditions. Opus Genetics, focusing on gene therapies for inherited retinal diseases, has seen its stock jump 60.3% this year, with promising early data and regulatory support. Analysts rate it a strong buy, suggesting a potential 285-345% upside. EyePoint, with its long-lasting implant for wet age-related macular degeneration and diabetic macular edema, has seen its stock surge 107.5% this year. Phase three trials are underway, with key data expected mid-2026, and analysts predict a potential 100-308% upside. These companies highlight biotechs high-stakes thrill, where one good readout could change everything for patients and investors.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.